Section: Contact Information

First Name: Peter
Last Name: de Blank
Institution: University Hospitals Rainbow Babies & Children's Medical Center
Address 1: 11100 Euclid Avenue
City: Cleveland
State/Province/Region: OH
Country: US
Zip/Postal Code: 44106
Phone Number: 216-844-3345
Alternate Phone Number: 216-844-3212
Email Address: peter.deblank@UHhospitals.org

Section: Project Requirements and Description

Group: Requirements to submit AOI
A comprehensive review of previously published data has been completed. Yes
The specific aims are clear and focused. Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. Yes
Project Title: The Effect of NF1 Status on Late Outcomes in Adults Survivors of Childhood Cancer
Planned research population (eligibility criteria): Survivors within the expansion cohort
Proposed specific aims:
1. Determine the effect of NF1 status on long-term functional outcomes (i.e. psychological distress, learning or memory problems, academic attainment and function, pain) in adult survivors of childhood cancer. Note: this aim would be assessed twice, once in all diagnoses and once in those with astrocytomas.

2. Examine the association between NF1 status and socioeconomic attainment (i.e. marital status, employment, independent living, household income) in adult survivors of childhood cancer. Note: this aim would be assessed twice, once in all diagnoses and once in those with astrocytomas.

3. Explore the association between NF1 status and chronic health conditions and second malignant neoplasm.

Will the project require non-CCSS funding to complete? No
If yes, what would be the anticipated source(s) and timeline(s) for securing funding? 
**Group: Does this project require contact of CCSS study subjects for:**

Additional self-reported information: No
Biological samples: No
Medical record data: No
If yes to any of the above, please briefly describe:

**Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)**

Second Malignancy: Secondary
Chronic Disease: Secondary
Psychology / Neuropsychology: Primary
Genetics:
Cancer Control:
Epidemiology / Biostatistics: Secondary

**Section: Outcomes or Correlative Factors**

Late mortality:
Second Malignancy: Secondary

**Group: Health Behaviors**

Tobacco:
Alcohol:
Physical activity:
Medical screening:
Other:
If other, please specify:

**Group: Psychosocial**

Insurance:
Marriage: Primary
Education: Primary
Employment: Primary
Other: Primary
If other, please specify: household income

**Group: Medical Conditions**

Hearing/Vision/Speech: Correlative Factors
Hormonal systems:
Heart and vascular:
Respiratory:
Digestive:
Surgical procedures:
Brain and nervous system: Primary
Other:
If other, please specify:

**Group: Medications**

Describe medications:

**Group: Psychologic/Quality of Life**

BSI-18: Primary
SF-36: Primary
CCSS-NCQ: Primary
PTS: Primary
PTG: Primary
Other:
If other, please specify:

**Group: Other**

Pregnancy and offspring:
Family history:
Chronic conditions (CTCAE v3): Secondary
Health status:

**Group: Demographic**

Age: Correlative Factors
Race: Correlative Factors
Sex: Correlative Factors
Other:
If other, please specify:

**Group: Cancer treatment**

Chemotherapy: Correlative Factors
Radiation therapy: Correlative Factors
Surgery: Correlative Factors

**Section: Anticipated Sources of Statistical Support**

CCSS Statistical Center: Yes
Local institutional statistician:
If local, please provide the name(s) and contact information of the statistician(s) to be involved.
Will this project utilize CCSS biologic samples?: No
If yes, which of the following?:
If other, please explain:

**Section: Other General Comments**
This will be designed as a case-control study matching survivors with NF1 with survivors without NF1 on diagnosis, treatment, age at diagnosis, gender and race.